ヨシダ ケン   YOSHIDA KEN
  吉田 謙
   所属   関西医科大学  放射線科学講座
   職種   准教授
論文種別 原著(症例報告除く)
言語種別 英語
査読の有無 査読あり
表題 Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
掲載誌名 正式名:Cancers
略  称:Cancers (Basel)
ISSNコード:20726694
掲載区分国外
巻・号・頁 13(8),pp.1856
著者・共著者 Yamazaki H, Suzuki G, Masui K, Aibe N, Shimizu D, Kimoto T, Yoshida K, Nakamura S, Okabe H.
発行年月 2021/04
概要 To examine the efficacy of dose escalating radiotherapy into patients with cT3b
or T4 localized prostate cancer, we compared Group A (86 conventional dose
external beam radiotherapy: EBRT group, treated with 70-72 Gy) and group B (39
high dose EBRT group (HDEBRT group, 74-80 Gy) and 124 high-dose-rate
brachytherapy (HDR) + EBRT (HDR boost)) using multi-institutional retrospective
data. The actuarial 5-year biochemical disease-free survival (bDFS) rate,
prostate cancer specific survival rate (PSS), and overall survival rate (OS)
were 75.8%, 96.8%, and 93.5%. Group B showed superior 5-year bDFS rate (81.2%)
as compared to the group A (66.5%) (p < 0.0001) with a hazard ratio of 0.397.
Equivocal 5-year PSS (98.3% and 94.8% in group B and group A) and OS (both
93.7%) were found between those groups. Accumulated late grade ≥ 2 toxicities in
gastrointestinal and genitourinary tracts were similar among those three groups.
Therefore, both HDEBRT and HDR boost could be good options for improving the
bDFS rate in cT3-T4 localized prostate cancer without affecting PSS and OS.
DOI 10.3390/cancers13081856
PMID 33924563